Loading stock data…
MTNB
$0.70+0.05 (+7.47%)
Market ClosedLast close May 1
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Matinas BioPharma Holdings, Inc. in the Healthcare sector is trading at $0.70. The stock is currently near its 52-week low of $0.48, remaining 32.8% below its 200-day moving average. Technical signals show overbought RSI of 83 and bullish MACD crossover, explaining why MTNB maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 83) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.70
Potential Upside
5%
Whystock Fair Value$0.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocry...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-498.18%
Volume
Today's trading volume
33,356
